Introduction
Oxidative stress has been implicated in the pathophysiology of heart failure (HF) as well as other disease states. the downstream consequences may lead to disease progression and adverse outcomes.
1 As one of the most abundant circulating antioxidants in the body, high-density lipoprotein (HDL) serves as an important regulator of oxidative stress, but the major focus has been on its role in reverse cholesterol transport as well as its effects on countering the pathogenesis of atherosclerosis. 3 The clinical relevance of HDL-cholesterol in HF has only been recently appreciated, with data from epidemiological studies recognizing low HDL-cholesterol as an important predictor of incident HF. 4, 5 Circulating paraoxonase-1 (PON-1) has long been associated with antioxidant functions of HDL, being the major 'detoxification' protein that is bound to apolipoprotein A1 in the HDL particle. 6 PON-1 catalytic activity within crude serum mixtures has traditionally been measured by quantifying enzymatic hydrolysis rates of two known in vitro substrates, with functional activities named paraoxonase (hydrolyses organophosphates, such as paraoxon) and arylesterase (hydrolyses aromatic esters, such as phenyl acetate) activities. 3, 7 We have recently demonstrated that in a cohort of stable cardiac patients with HF undergoing cardiac catheterization, diminished serum arylesterase (ArylE) activity, a functional measure of PON-1 activity, corresponds to higher rates of long-term major adverse cardiac events including death, myocardial infarction, and stroke. 8 Herein, we examined the impact of HDL antioxidant function on disease progression of chronic HF by measuring serum ArylE and paraoxonase activities levels in ambulatory patients with chronic HF.
Methods

Study population
A total of 299 subjects with HF were enrolled from the Atlanta Cardiomyopathy Consortium, a prospective cohort study conducted between 2007 and 2013 enrolling outpatients with HF from three university-affiliated hospitals in the greater metropolitan Atlanta area. The inclusion criteria included age older than 18 years, ability to understand and sign written informed consent to participate, and a diagnosis of HF with either reduced or preserved ejection fraction (EF). The diagnosis of HF with preserved EF required, in addition to the clinical diagnosis of HF, an elevated BNP level (>200 pg/dL) and/or echocardiographic evidence of diastolic dysfunction. Exclusion criteria included congenital heart disease, previous heart transplant, known cardiac infiltrative disease (e.g. amyloidosis), previous other solid organ transplantation, and end-stage HF requiring outpatient continuous inotrope infusion. Creatinine clearance was calculated using the Cockcroft-Gault formula. Patients were followed up prospectively for HF events [death, transplant, and left ventricular assist device (LVAD) implantation] and HF-related hospitalizations. The Emory University Institutional Review Board approved the research protocol, and all participants provided written informed consent.
Serum arylesterase activity and paraoxonase activity measurements
Blood samples were collected on enrolment for all patients and in 145 patients who had a clinic visit after 1 year. Serum ArylE activity and paraoxonase activity assays were measured by spectrometry in an open channel on an Architect ci8200 platform, and in a 96-well plate format (Spectramax 384 Plus, Molecular Devices, Sunnyvale, CA, USA), respectively, as previously described. 3 determined at 270 nm in 50-fold diluted serum (final) in reaction mixtures composed of 3.4 mM phenyl acetate (Sigma-Aldrich, St Louis, MO, USA), 9 mM Tris-HCl, pH 8, and 0.9 mM calcium chloride at 24 ∘ C. An extinction coefficient (at 270 nm) of 1310/M/cm was used for calculating units of ArylE activity, which are expressed as micromoles of phenyl acetate hydrolysed per minute per millilitre of serum. The intra-assay and interassay coefficients of variance for ArylE activity assay were 3.4% and 3.9%, respectively, on 20 replicates performed on 10 different days. For serum paraoxonase activity, the rate of generation of para-nitrophenol was determined at 405 nm in 40-fold diluted serum (final) in reaction mixtures composed of 1.5 mM paraoxon (Sigma-Aldrich), 10 mM Tris-HCl, pH 8, 1 M sodium chloride, and 2 mM calcium chloride at 24 ∘ C. An extinction coefficient (at 405 nm) of 17 000/M/cm was used for calculating units of paraoxonase activity, which is expressed as nanomoles of para-nitrophenol produced per minute per millilitre of serum. The intra-assay and interassay coefficients of variance for the high-throughput paraoxonase activity assay were 1.9% and 3.3%, respectively, on 30 replicates performed on 15 different days.
Statistical analysis
The Student t-test or analysis of variance (ANOVA) test for continuous variables, and 2 test for categorical variables were used to examine differences between the groups. Linear regression was used to study correlation of factors with ArylE activity. Survival and event rates were described with the Kaplan-Meier method. Cox proportional hazards regression was used to determine hazard ratios (HRs) and 95% confidence intervals (CIs) for events. In multivariable models, we adjusted for age, gender, diabetes mellitus, systolic blood pressure, calculated creatinine clearance, coronary artery disease (CAD), and HDL-cholesterol levels. The negative binomial regression model was used to obtain an estimate of the effect of ArylE activity on the rate of HF hospitalizations giving the skewed distribution in the frequency of hospitalizations. 9, 10 The negative binomial naturally accommodates the different probabilities for events across members of the population. General linear models with repeated measures were used to study the change of ArylE over time. A significant drop in ArylE activity over time was defined as a drop of ≥25% of the baseline activity. Table 1 describes the baseline characteristics of the study population. Baseline ArylE activity was normally distributed with a mean of 110.6 ± 29.9 μmol/min/mL. No significant difference in baseline characteristics was observed between groups with different ArylE activity. No difference was observed in ArylE activity between patients with preserved or reduced EF.
Results
Serum arylesterase activity and clinical variables
On univariate linear regression analysis, increased HDL-cholesterol levels ( = 0.61, P < 0.001), female gender ( = 8.2, P = 0.024), and ACE inhibitor/ARB use ( = 10.8, P = 0.01) were associated with increased activity of baseline ArylE activity, while log-transformed BNP ( = -3.1, P = 0.01) was inversely correlated with ArylE activity. However, on multivariate linear regression including basic demographics, medication use, and EF, only HDL-cholesterol ( = 0.63, P < 0.001) and ACE inhibitor/ARB use ( = 13.3, P = 0.01) were independently associated with increased baseline ArylE activity.
Baseline arylesterase activity and heart failure adverse outcomes
After a mean follow-up of 2.8 ± 1.1 years, 53 patients had HF events (42 deaths, 7 transplants, 4 ventricular assist devices), while 95 patients experienced a total of 283 HF-related hospitalizations. Distribution of HF-related hospitalizations is shown in the Supplementary material online, Figure S1 . Patients with low HDL-cholesterol (<40 mg/dL for men and <50 mg/dL for women) had a higher risk of HF events (log rank = 0.034) but not HF-related hospitalizations (P = 0.298) ( Figure 1A and B).
Patients who had HF events had significantly lower ArylE activity (102.4 ± 27.8 vs. 112.3 ± 30.2 μmol/min/mL, P = 0.028). Patients with low ArylE activity had a higher incidence of HF events (23.5% vs. 9.9%, for lowest vs. highest tertile, P = 0.031) and HF-related hospitalizations (49 vs. 20.2 per 100 patient-years for lowest vs. highest tertile, respectively). Patients with lower levels of ArylE activity have a significantly increased risk of HF events (HR for lowest vs. highest tertile of 2.6, 95% CI 1.3-5.5, P = 0.01) and HF-related hospitalizations (incidence rate ratio for lowest vs. highest tertile of 2.1, 95% CI 1.2-4.1, P = 0.016) ( Figure 1C and D, and Table 2 ). ArylE activity remained significant even after adjustment for age, gender, diabetes, systolic blood pressure, creatinine clearance, and CAD ( with available baseline HDL-cholesterol levels (n = 253), low ArylE activity was independently associated with adverse HF events and hospitalization, even after adjustment for HDL-cholesterol levels.
Follow-up arylesterase activity and heart failure outcomes
A total of 145 patients had a 1-year follow-up clinic visit and ArylE activity was reassessed. No significant difference was found in patients with follow-up levels and those without in regard to basic demographics and HF severity (EF and BNP) (Supplementary material online, Table S1 ). However, HF events were lower (9.7% vs. 25.3%, P = 0.001) in the group with available follow-up samples for ArylE activity measurement. A significant decrease in ArylE activity was observed on follow-up (-5.9 ± 28.6 μmol/min/mL, P = 0.015) (Figure 2A) . No significant correlation was found between basic demographics, medications, BNP, or EF and change in ArylE activity over time. When the change in ArylE activity over time was stratified by HF events, those who developed HF events had a trend of higher drop in ArylE activity over time (mean of -19.2 ± 37.3 vs. -4.4 ± 27.3 μmol/min/mL, for events and non-events, respectively, P = 0.066) ( Figure 2B ).
After adjustment for baseline level, low follow-up ArylE activity was also independently associated with increased HF events (lowest tertile vs. highest tertile, HR 6.0, 95% CI 1.04-34.7, adjusted P = 0.046] ( Table 2) . A drop in ArylE activity was associated with increased risk of HF events (40%, 95% CI 8-80% increased risk for every 10% drop; or HR 4.9, 95% CI 1.6-14.6 for a drop ≥25%, adjusted P-value for baseline levels of 0.01 and 0.005, respectively) ( Figure 3) . No correlation between follow-up ArylE activity and HF-related hospitalization was observed ( Table 2) .
Serum paraoxonase activity and heart failure outcomes
We also assessed paraoxonase activity (hydrolyses organophosphates, such as paraoxon) of PON-1 on baseline and on follow-up. Paraoxonase activity was positively skewed, with a median (interquartile range; IQR) baseline of 829 (350-1233) nmol/min/mL, which increased significantly on follow-up to 883 (351-1414) nmol/min/mL (P = 0.015). In contrast to ArylE activity, patients who had HF events did not have lower paraoxonase activity at baseline 
Validation of results and association with apolipoprotein A1
We validated our results using a longer follow-up time (5 years) of our previously published cohort of 830 patients with HF undergoing elective coronary angiography enrolled from the Cleveland Clinic Genebank database (Supplementary material online, Methods). The mean age was 67 ± 11 years, 60% were males, and 76% had CAD (Supplementary material online, Table S2 ). Mean ArylE activity was 94.2 ± 26.3 μmol/min/mL, and mean apolipoprotein A1 was 113.6 ± 25.2 mg/dL. There was a positive correlation between apolipoprotein A1 and ArylE activity ( = 0.42, R 2 = 0.16, P < 0.001). In this cohort, both ArylE activity and apolipoprotein A1 were associated with 5-year all-cause mortality. However, when both were included in one model, only ArylE activity was significantly associated with all-cause mortality (Supplementary material online, Table S3 ).
Discussion
We demonstrate that in an outpatient population of chronic HF, impaired antioxidant function of HDL as measured by serum ArylE activity was associated with adverse HF events and HF-related hospitalizations. We also observed a significant decrease in ArylE activity over time, mainly in patients who developed adverse HF events. We did not see any correlation between HF events or hospitalizations and paraoxonase activity. Furthermore, using our previously published cohort, we found ArylE activity to be independent of apolipoprotein A1 levels in predicting adverse outcomes. These findings are supportive of our initial observations, and confer HDL as an important mediator that may serve to prevent disease progression in HF. myocardial oxidative stress and mitochondrial dysfunction.
13,17
Thus, antioxidant activity may play a major role in modifying oxidative stress and subsequently may prevent progression of HF.
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Circulating PON-1 is the major 'detoxification' protein that is bound to apolipoprotein A1 in the HDL particle.
3 PON-1 has been shown to be involved in inhibiting LDL oxidation, cholesterol efflux, monocyte binding and transmigration, plaque inflammation, as well as destroying oxidized phospholipids and thus decreasing atherosclerosis and plaque formation. 18, 19 Furthermore, by hydrolysing homocysteine thiolactones, PON-1 may prevent endothelial dysfunction and vascular damage. 7, 20, 21 The clinical significance of PON-1 activity is still controversial. Concordant with the atheroprotective role of ArylE activity, several studies have shown low activity to be associated with increased CAD risk, CAD severity, endothelial dysfunction, 22 worse collateral flow, and adverse cardiovascular outcomes. 7,19,20,23 -25 However, in contrast to this, a few other studies showed high activity to be associated with increased CAD severity, coronary calcification, and increased risk of myocardial infarction, 19, 26, 27 while other studies have not shown any such associations. 28, 29 Only a few studies assessed serum ArylE activity in the setting of HF. In our previous report, we found patients with HF to have diminished ArylE activity in comparison with the healthy control group. 8 We also showed that diminished ArylE activity is associated with all-cause mortality, myocardial infarction, and stroke in patients with ischaemic cardiomyopathy. 3 We have largely related this to the antiatherogenic role of PON-1 since the study population included mainly patients with ischaemic HF. However, in this group of patients with mixed ischaemic and non-ischaemic HF, we also showed a significant association with adverse HF events (death, cardiac transplantation, and LVAD implantation). Furthermore, using long-term data from our previously cohort, 3 we found ArylE activity to carry more prognostic information above and beyond the levels of apolipoprotein A1. Taken together, the association of diminished serum ArylE activity and adverse outcomes is probably independent of the underlying aetiology of HF, and more reflective of antioxidative properties of HDL than the levels . It is still unclear what the factors that influence diminished serum ArylE activity are. In our population, only ACE inhibitor/ARB use and baseline HDL-cholesterol levels were independent predictors of high baseline ArylE activity. However, no factor was associated with increased ArylE activity on follow-up. Several other studies have shown an increase in ArylE activity after statin treatment; 30 -32 however, only one was a randomized control study. 30 Since diminished PON-1 activity is linked to adverse outcomes in patients with HF, targeting those with diminished PON-1 activity may provide a protective role in HF. Although previous trials that used antioxidants or statins failed to show mortality benefit, 33 -38 these trials were testing the effect of the intervention regardless of the oxidative status of the patient. Thus, the beneficial effect could be masked by those with low oxidative status, who may not benefit from the intervention. Whether identifying the heightened risk patients, like those with diminished PON-1 activity, could affect HF outcomes needs to be further investigated.
Interestingly, we observed a discordance between the two PON-1 activities in predicting adverse HF outcomes. These findings are consistent with our previous observations of no association between paraoxonase activity and subclinical myocardial necrosis and adverse cardiovascular outcomes in patients with CAD undergoing coronary angiography. 3 The unique relationship between the two PON-1 activity measurements is largely the result of a very strong association between serum paraoxonase activity and its underlying genetic determinants, which may also explain why serum ArylE activity is normally distributed whereas serum paraoxonase activity was not.
In clinical practice, clinicians tend to treat HF patients based on their EF, without considering the underlying mechanism. Our findings are important in the context that, among different HF patients, there is a variable involvement of different mechanisms, such as inflammation, 39 -41 oxidative stress, 11, 12 microvascular rarefaction, 42 pressure overload, 43 endothelial dysfunction, 1 etc. Thus, profiling HF patients in a more mechanistically driven way may help in identifying patients at heightened risk and provide a more individualized HF therapy. Whether treating patients with low PON-1 activity with statins or other medications has an impact on outcome needs to be further investigated. 44 
Study strengths and limitations
Our study is the first study to assess serial PON-1 activity in outpatients with HF and correlate that with their prospective outcomes. However, the small sample size and low number of patients with follow-up samples are the major limitations of our study. Also, it is worth noting that serum paraoxonase and ArylE activities used substrates that are not the endogenous substrates for PON-1, but are used because they are not readily influenced by other esterases/lactonases in serum, and are presumed to reflect the underlying catalytic activity of PON-1. 8 We did not assess genotyping or circulating levels of PON-1 that may also impact the prognostic value of ArylE activity in this population.
Conclusion
Diminished serum PON-1 activity, measured by ArylE activity, is associated with adverse outcomes in stable outpatients with HF.
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